UAE-based Ovasave gets $1.2M to expand across the region

Abu Dhabi-based FemTech startup Ovasave raised $1.2 million from a mix of regional and international investors, including PlusVC, Annex Investments, and New York-based 25madison. In addition, backing came from UAE and Saudi-based strategic angel investors and prominent family offices.

The company's platform combines at-home hormone testing, virtual consultations, personalised supplement protocols, and access to top fertility clinics for fertility preservation (egg freezing). Positioned as disruptors in fertility and women's hormonal health, Ovasave has also established a growing corporate benefits scheme that helps organisations support employees' reproductive health as part of their workplace wellbeing programmes.

The newly raised capital will be used to support regional expansion across the GCC, scale corporate partnerships, and launch the next phase of Ovasave's mobile app, which will include menstrual cycle tracking, symptom monitoring, access to care, and AI-driven treatment protocols. Ovasave will also address a historically overlooked stage of women's health, offering a broader range of services targeting perimenopause and menopause.

Specifically, the company will expand its operations to Saudi Arabia this summer, with broader regional growth across the MENA region being part of its 3-year expansion strategy.

The news comes as the UAE accelerates national reforms in healthcare and women's rights, offering a timely window for FemTech innovation. Ovasave is registered with the Department of Health - Abu Dhabi and supported by Abu Dhabi's global tech ecosystem, Hub71, further aligning it with the nation's broader digital and preventive health strategies.